<DOC>
	<DOCNO>NCT00084786</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy docetaxel work different way stop tumor cell divide stop grow die . Giving gefitinib docetaxel may kill tumor cell . PURPOSE : This phase I trial study side effect best dose gefitinib give docetaxel treat patient advance solid tumor .</brief_summary>
	<brief_title>Gefitinib Docetaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose gefitinib administer docetaxel patient advance solid tumor . - Determine safety efficacy regimen patient . - Determine pharmacokinetics regimen patient . OUTLINE : This dose-escalation study gefitinib . Patients receive oral gefitinib daily day 1 2 docetaxel IV 1 hour day 3 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gefitinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 3-42 patient accrue study .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor Failed standard treatment OR standard treatment exist Measurable evaluable indicator lesions No uncontrolled CNS metastasis ( i.e. , know CNS lesion progressive [ e.g. , ≥ 25 % growth ] , symptomatic , and/or require escalate dos corticosteroid ) PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 2.0 time ULN Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 55 mL/min Cardiovascular No congestive heart failure No recent myocardial infarction No unstable angina No uncontrolled hypertension Pulmonary No clinically active interstitial lung disease Chronic , stable , asymptomatic radiographic change allow Ophthalmic No corneal abnormality No history dry eye syndrome ocular surface diseases Other No know severe hypersensitivity gefitinib excipients No unstable systemic disease No active infection No significant medical history unstable medical condition Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No sperm donation 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 3 week since prior chemotherapy No 2 prior chemotherapy regimens metastatic cancer No prior docetaxel Endocrine therapy See Disease Characteristics Radiotherapy At least 3 week since prior radiotherapy major bone marrowcontaining area Surgery Not specify Other No prior gefitinib erlotinib No prior epidermal growth factor receptor tyrosine kinase inhibitor More 30 day since prior nonapproved investigational drug No concurrent administration follow CYP3A4 inhibitor inducer : Ketoconazole Itraconazole Clarithromycin Erythromycin Grapefruit juice Troleandomycin Diltiazem Verapamil Rifampin Phenytoin Carbamazepine Barbiturates Hypericum perforatum ( St. John 's wort ) No concurrent warfarin No concurrent drug cause significant sustained elevation gastric pH ( pH ≥ 5 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>